Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab and PEG-interferon alfa-2b in Metastatic or Unresectable Carcinoid Tumors
NCT00055809Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Jan 2003
- Primary completion
- Jun 2007
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, peginterferon alfa-2b in Carcinoid Tumor (CT), sponsored by National Cancer Institute. Started Jan 2003; status: completed.
02
Drugs
bevacizumabpeginterferon alfa-2b
03
Conditions
Carcinoid Tumor (CT)
Beyond the preview
Go deeper on NCT00055809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055809.